THE 2-MINUTE RULE FOR RIPA-56

Just one important shortcoming of norBNI, the KOR antagonist made use of most broadly in preclinical studies, may be the persistent effects of one administration [20, 24]. A short acting, selective antagonist is not simply valuable for clinical improvement, but will also for experimental layouts that need ligands to reverse speedily ample for repea